Diabetes Prevention

Perspectives and Actions of One Company


      Diabetes, particularly type 2 diabetes mellitus (T2DM), has reached epidemic proportions in the U.S. and globally, highlighting the need for major improvements in treatment strategies for detecting, preventing, and slowing disease progression. Despite escalating treatment costs, diabetes care remains largely substandard, with hospitalizations for late-stage complications in particular placing a major burden on the healthcare system. Although considerable advances have been made in identifying the risk factors of diabetes and developing treatments, goals targeting prevention have remained elusive. Although there is currently no consensus regarding terminology among public health practitioners, the concept of prevention in terms of diabetes care runs the gamut from interventions used to avoid disease in individuals without risk factors (primordial prevention) to prevention of the consequences of established complications (quaternary prevention).
      Given the worldwide prevalence of diabetes, it is crucial to improve the quality of care for those diagnosed with overt diabetes, as well as those who have been identified as at risk for developing the disease. Earlier screening enables undiagnosed, asymptomatic individuals with diabetes to be identified sooner, managed more effectively, and where necessary, treated with the appropriate pharmacotherapeutic options in a timely manner. All stakeholders (including government, industry, professional, and patient groups) must partner in concert to address these vital issues so that treatment goals ultimately may be realized.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to American Journal of Preventive Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • CDC
        National diabetes fact sheet.
        • Narayan K.M.V.
        • Boyle J.P.
        • Thompson T.J.
        • Sorensen S.W.
        • Williamson D.F.
        Lifetime risk for diabetes mellitus in the U.S..
        JAMA. 2003; 290: 1884-1890
        • Eckel R.H.
        • Kahn S.E.
        • Ferranni E.
        • et al.
        Obesity and type 2 diabetes: what can be unified and what needs to be individualized?.
        Diabetes Care. 2011; 34: 1424-1430
        • CDC
        Prevalence of overweight and obesity among adults with diagnosed diabetes—U.S., 1988-1994 and 1999-2002.
        • Wherrett D.K.
        • Daneman D.
        Prevention of type 1 diabetes.
        Pediatr Clin North Am. 2011; 58: 1257-1270
        • American Diabetes Association
        Standards of medical care in diabetes–2013.
        Diabetes Care. 2013; 36: S11-S66
        • Mensah G.A.
        • Dietz W.H.
        • Harris V.B.
        • et al.
        Prevention and control of coronary heart disease and stroke—nomenclature for prevention approaches in public health.
        Am J Prev Med. 2005; 2: 152-157
        • National Diabetes Education Program
        Working together to manage diabetes: a guide for pharmacy, podiatry, optometry, and dental professionals.
        • Huang E.S.
        • Basu A.
        • O'Grady M.
        • Capretta J.C.
        Projecting the future diabetes population size and related costs for the U.S..
        Diabetes Care. 2009; 32: 2225-2229
        • Knowler W.C.
        • Barrett-Connor E.
        • Fowler S.E.
        • et al.
        • Diabetes Prevention Program Research Group
        Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.
        N Engl J Med. 2002; 346: 393-403
        • Ackermann R.T.
        • Finch E.A.
        • Caffrey H.M.
        • Lipscomb E.R.
        • Hays L.M.
        • Saha C.
        Long-term effects of a community-based lifestyle intervention to prevent type 2 diabetes: the DEPLOY extension pilot study.
        Chronic Illn. 2011; 7: 279-290
        • Perreault L.
        • Pan Q.
        • Mather K.J.
        • Watson K.E.
        • Hamman R.F.
        • Kahn S.E.
        • Diabetes Prevention Program Research Group
        Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study.
        Lancet. 2012; 379: 2243-2251
        • Kilpatrick E.S.
        • Rigby A.S.
        • Atkin S.L.
        The Diabetes Control and Complications Trial: the gift that keeps giving.
        Nat Rev Endocrinol. 2009; 5: 537-545
        • Holman R.R.
        • Paul S.K.
        • Bethel M.A.
        • Matthews D.R.
        • Neil H.A.
        10-year follow-up of intensive glucose control in type 2 diabetes.
        N Engl J Med. 2008; 359: 1577-1589
        • Inzucchi S.E.
        • Bergenstal R.M.
        • Buse J.B.
        • et al.
        Management of hyperglycaemia in type 2 diabetes: a patient-centered approach.
        Diabetes Care. 2012; 35: 1364-1379
        • Handelsman Y.
        • Mechanick J.I.
        • Blonde L.
        • et al.
        • AACE Task Force for Developing Diabetes Comprehensive Care Plan
        American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for developing a diabetes mellitus comprehensive care plan.
        Endocr Pract. 2011; 17: 1-53
        • Hart J.T.
        Rule of halves: implications of increasing diagnosis and reducing dropout for future workload and prescribing costs in primary care.
        Br J Gen Pract. 1992; 42: 116-119
        • Narayan K.M.
        • Echouffo-Tcheugui J.B.
        • Mohan V.
        • Ali M.K.
        Analysis & commentary: global prevention and control of type 2 diabetes will require paradigm shifts in policies within and among countries.
        Health Aff. 2012; 31: 84-92
        • U.S. Preventive Services Task Force
        Screening for type 2 diabetes mellitus in adults: U.S Preventive Services Task Force recommendation statement.
        Ann Intern Med. 2008; 148: 846-854
        • Moses A.C.
        • Handlesman Y.
        • Einhorn D.
        Effectiveness of primary care-relevant treatments for obesity in adults [Letter to the editor].
        Ann Intern Med. 2012; 156: 248-249
        • Sheehy A.M.
        • Flood G.E.
        • Tuan W.J.
        • Liou J.I.
        • Coursin D.B.
        • Smith M.A.
        Analysis of guidelines for screening diabetes mellitus in an ambulatory population.
        Mayo Clin Proc. 2010; 85: 27-35
        • Kahn R.
        • Alperin P.
        • Eddy D.
        • et al.
        Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis.
        Lancet. 2010; 375: 1365-1374
        • Villarivera C.
        • Wolcott J.
        • Jain A.
        • Zhang Y.
        • Goodman C.
        Analysis & commentary: the U.S. Preventive Services Task Force should consider a broader evidence base in updating its diabetes screening guidelines.
        Health Aff. 2012; 31: 35-42
        • CDC
        National Diabetes Prevention Program.
        • Egede L.E.
        • Gebregziabher M.
        • Dismuke C.E.
        • et al.
        Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement.
        Diabetes Care. 2012; 35: 2533-2539
        • Jha A.K.
        • Aubert R.E.
        • Yao J.
        • Teagarden J.R.
        • Epstein R.S.
        Greater adherence to diabetes drugs is linked to less hospital use and could save nearly $5 billion annually.
        Health Aff. 2012; 31: 1836-1846
        • Novo Nordisk A/S
        Milestones in Novo Nordisk's history.
        • Hagedorn Research Institute
        • Steno Diabetes Center
        • Gæde P.
        • Vedel P.
        • Larsen N.
        • Jensen G.V.
        • Parving H.H.
        • Pedersen O.
        Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes.
        N Engl J Med. 2003; 348: 383-393
        • Novo Nordisk
        Global R&D facts and figures.